Skip to main content

Peer Review reports

From: Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Original Submission
14 Mar 2022 Submitted Original manuscript
23 Jul 2022 Reviewed Reviewer Report
14 Sep 2022 Reviewed Reviewer Report
15 Nov 2022 Author responded Author comments - ZHU Xinsheng
Resubmission - Version 2
15 Nov 2022 Submitted Manuscript version 2
16 Nov 2022 Reviewed Reviewer Report
29 Nov 2022 Author responded Author comments - ZHU Xinsheng
Resubmission - Version 3
29 Nov 2022 Submitted Manuscript version 3
Publishing
5 Dec 2022 Editorially accepted
30 Dec 2022 Article published 10.1186/s12916-022-02696-4

You can find further information about peer review here.

Back to article page